Protection abilities of influenza B virus DNA vaccines expressing hemagglutinin, neuraminidase, or both in mice

Acta Virologica

Volumn 52, Issue 2, 2008, Pages 107-112

  Fang, F ^a   Cai, X Q ^a   Chang, H Y ^a   Wang, H D ^a   Yang, Z D ^c   Chen, Z ^a,b,c  

^a HUNAN NORMAL UNIVERSITY   (China)

^b WUHAN INSTITUTE OF VIROLOGY   (China)

^c SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS   (China)

Author keywords

DNA vaccine; Hemagglutinin; Influenza B virus; Neuraminidase

Indexed keywords

DNA VACCINE; INFLUENZA VACCINE; PLASMID DNA; VIRUS HEMAGGLUTININ; VIRUS SIALIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; ELECTROPORATION; FEMALE; IMMUNIZATION; INFLUENZA; INFLUENZA VIRUS A; LUNG; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SURVIVAL RATE; WEIGHT CHANGE;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; NEURAMINIDASE; VACCINES, DNA; VIRAL PROTEINS;

AVIAN INFECTIOUS BRONCHITIS VIRUS; INFLUENZA B VIRUS; MUS;

EID: 45849121702     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Aihara H, Miyazaki J (1998): Gene transfer into muscle by electroporation in vivo. Nat. Biotechnol. 16, 867-870.
2. Bianchi E, Liang X, Ingallinella P, Finotto M, Chastain MA, Fan J, Fu TM, Song HC, Horton MS, Freed DC, Manger W, Wen E, Shi L, Ionescu R, Price C, Wenger M, Emini EA, Cortese R, Ciliberto G, Shiver JW, Pessi A (2005): Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor. J. Virol. 79, 7380-7388.
3. Chen JJ, Fang F, Li XZ, Chang HY, Chen Z (2005): Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation. Vaccine 23, 4322-4328.
4. Chen Z, Kadowaki S, Hagiwara Y, Yoshikawa T, Sata T, Kurata T, Tamura. S (2001): Protection against influenza B virus infection by immunization with DNA vaccines. Vaccine 19, 1446-1455.
5. Chen Z, Kurata T, Tamura S (2000): Identification of effective constituents of influenza vaccine by immunization with plasmid DNAs encoding viral proteins. Jpn. J. Infect. Dis. 53, 219-228.
6. Chen Z, Natsuo K, Asanuma H, Takahashi H, Iwasaki T, Suzuki Y, Aizawa C, Kurata T, Tamura S (1999): Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin-and neuraminidase-expressing DNAs. Vaccine 17, 653-659
7. Chen Z, Sahashi Y, Matsuo K, Asanuma H, Takahashi H, Iwasaki T, Suzuki Y, Aizawa C, Kurata T, Tamura S (1998): Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza. Vaccine 16, 1544-1549.
8. Davis HL (1997): Plasmid DNA expression systems for the purpose of immunization. Curr. Opin. Biotechnol. 8, 635-646.
9. Grifantini R, Finco O, Bartolini E, Draghi M, Del Giudice G, Kocken C, Thomas A, Abrignani A, Grandi G (1998): Multi-plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmid. Eur. J. Immunol. 28, 1225-1232.
10. Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, Kimura K, Kiso M, Shimizu H, Kawakami C, Koike K, Mitamura K, Kawaoka Y (2007): Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297, 1435-1442.
11. Hinkula J, Svanholm C, Schwartz S, Lundholm P, Brytting M, Engstrom G, Benthin R, Glaser H, Sutter G, Kohleisen B, Erfle V, Okuda K, Wigzell H, Wahren B (1997): Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. J. Virol. 71, 5528-5539.
12. Hoffmann E, Mahmood K, Yang CF, Webster RG, Greenberg HB, Kemble G (2002): Rescue of influenza B virus from eight plasmids. Proc. Natl. Acad. Sci. USA 99, 11411-11416.
13. Johansson BE, Kilbourne ED (1993): Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition. J. Virol. 67, 5721-5723.
14. Leitner WW, Seguin MC, Ballou WR, Seitz JP, Schultz AM, Sheehy MJ, Lyon JA (1997): Immune responses induced by intramuscular or gene gun injection of protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from Plasmodium berghei malaria parasites. J. Immunol. 159, 6112-6119.
15. Lima KM, Santos SA, Lima VM, Coelho-Castelo AA, Rodrigues JM Jr, Silva CL (2003): Single dose of a vaccine based on DNA encoding mycobacterial hsp65 protein plus TDM-loaded PLGA microspheres protects mice against a virulent strain of Mycobacterium tuberculosis. Gene Ther. 10, 678-685.
16. Lin CH, Huang YC, Chiu CH, Huang CG, Tsao KC, Lin TY (2006): Neurologic manifestations in children with influenza B virus infection. Pediatr. Infect. Dis. J. 25, 1081-1083.
17. Liu MA (2003): DNA vaccines: a review. J. Intern. Med. 253, 402-410.
18. Lodmell DL, Parnell MJ, Weyhrich JT, Ewalt CL (2003): Canine rabies DNA vaccination: a single-dose intradermal injection into ear pinnae elicits elevated and persistent levels of neutralizing antibody. Vaccine 21, 3998-4002.
19. Matsuzaki Y, Sugawara K, Takashita E, Muraki Y, Hongo S, Katsushima N, Mizuta K, Nishimura H (2004): Genetic diversity of influenza B virus: the frequent reassortment and cocirculation of the genetically distinct reassortant viruses in a community. J. Med. Virol. 74, 132-140.
20. McCullers JA, Wang GC, He S, Webster RG (1999): Reassortment and insertion-deletion are strategies for the evolution of influenza B viruses in nature. J. Virol. 73, 7343-7348.
21. Mizuta K, Itagaki T, Abiko C, Murata T, Takahashi T, Murayama S (2004): Epidemics of two Victoria and Yamagata influenza B lineages in Yamagata, Japan. Epidemiol. Infect. 132, 721-726.
22. Moraes MP, Mayr GA, Mason PW, Grubman MJ (2002): Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine 20, 1631-1639.
23. Murphy BR, Webster RG (1996): Orthomyxoviruses. In Fields BN, Knipe DM, Howley PM (Eds): Fields Virology. Lippincott-Raven, Philadelphia, New York, pp. 1397-1445.
24. Nicholson KG, Wood JM, Zambon M (2003): Influenza. Lancet 362, 1733-1745.
25. Osterhaus AD, Rimmelzwaan GF, Martina BE, Bestebroer TM, Fouchier RA (2000): Influenza B virus in seals. Science 288, 1051-1053.
26. Reed LJ, Muench H (1938): A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493-497.
27. Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K (1990): Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 175, 59-68.
28. Shaw MW, Xu X, Li Y, Normand S, Ueki RT, Kunimoto GY, Hall H, Klimov A, Cox NJ, Subbarao K (2002): Reappearance and global spread of variants of influenza B/Victoria/2/87 lineage viruses in the 2000-2001 and 2001-2002 seasons. Virology 303, 1-8.
29. Tamura SI, Asanuma H, Ito Y, Hirabayashi Y, Suzuki Y, Nagamine T, Aizawa C, Kurata T, Oya A (1992): Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur. J. Immunol. 22, 477-481.
30. Tamura S, Tanimoto T, Kurata T (2005): Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn. J. Infect. Dis. 58, 195-207.
31. Webster RG, Cox N, Stoehr A (2002): WHO Manual on Animal Influenza Diagnosis and Surveillance. www.wpro.who.int/NR/rdonlyres/EFD2B9A7-2265-4AD0- BC98-97937B4FA83C/0/manualonanimalaidiagnosisandsurveillance.(pdf)
32. Xu X, Lindstrom SE, Shaw MW, Smith CB, Hall HE, Mungall BA, Subbarao K, Cox NJ, Klimov A (2004): Reassortment and evolution of current human influenza A and B viruses Virus Res. 103, 55-60.
33. Zhang F, Chen J, Fang F, Zhou Y, Wu J, Chang H, Zhang R, Wang F, Li X, Wang H, Ma G, Chen Z (2005): Maternal immunization with both hemagglutinin- and neuraminidase-expressing DNAs provides an enhanced protection against a lethal influenza virus challenge in infant and adult mice. DNA Cell Biol. 24, 758-765.